Stem cell combo shows promise for deadly transplant complication

NCT ID NCT07568535

Not yet recruiting Disease control Sponsor: Mesoblast, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether adding a stem cell therapy called remestemcel-L to the drug ruxolitinib can help adults with severe, steroid-resistant graft-versus-host disease (GVHD) after a bone marrow transplant. GVHD occurs when donor immune cells attack the patient's body. The study will enroll 180 participants and measure how many achieve a response by day 28 without needing extra immune-suppressing treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remestemcel-L (a type of stem cell) plus ruxolitinib
What this could lead to: If successful, this combination could offer a new treatment option for severe graft-versus-host disease, potentially improving survival and reducing the need for additional immune-suppressing drugs.
What could go wrong: This is an early-stage Phase 3 trial with only 180 participants, so results may not apply to everyone. The treatment involves stem cells and strong immune suppression, which carry risks of infection or other complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GVHD - GRAFT-VERSUS-HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GVHD - GRAFT-VERSUS-HOST DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.